The following criteria is provided for health care professionals.

Inclusion Criteria:

- Pathologically documented,multiple myeloma relapsed or refractory progressive disease after at least 3 lines of therapy for multiple myeloma.

Prior therapeutic treatment or regimens must include proteasome inhibitors (e.g. bortezomib) and immunomodulatory drugs (e.g. lenalidomide).

• Willing and able to undergo bone marrow aspirate per protocol (with or without bone marrow biopsy per institutional guidelines).
• Measurable disease per the IMWG response criteria
• Hematological function, as follows, without transfusion support:
• Absolute neutrophil count ≥ 1.0 X 109/L,
• Platelet count ≥ 75 X 109/L (in patients with < 50% of bone marrow nucleated cells were plasma cells) or ≥ 50 X 109/L (in patients with ≥ 50% of bone marrow nucleated cells were plasma cells) without transfusion or growth factor support
• Hemoglobin > 8 g/dL (> 80 g/L)
• Adequate renal and hepatic function
• Left ventricular ejection fraction (LVEF) > 50%

Exclusion Criteria:

• Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study
• Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 days prior to study day 1
• Multiple myeloma with IgM subtype
• Glucocorticoid therapy (prednisone > 30 mg/day or equivalent) within 7 days prior to study day
• Autologous stem cell transplant less than 90 days prior to study day 1
• POEM syndrome, Plasma cell leukemia, Waldenstrom's macroglobulinemia or Amyloidosis
• Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association > class II)
• A baseline ECG QTcF > 470 msec